Astra Merck Atacand Launch Will Have Support From 1,000 Sales Reps
Executive Summary
A newly expanded Astra Merck 1,000-member sales force will promote the angiotensin II inhibitor Atacand, which received FDA approval June 4.
You may also be interested in...
Atacand Approval Provides Alternative To ACE Inhibitors For Heart Failure
AstraZeneca's angiotensin receptor blocker Atacand can be used as an alternative to angiotensin-converting enzyme inhibitors in reducing risk of cardiovascular mortality and hospitalization in heart failure patients
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011